Based on the modeling scores, we analyzed drug sensitivity of the high or low-CuRA patient group to provide guidance on drug administration. SFT2D1, as a key gene involved in the progression of cervical cancer, it was associated with the cuproptosis-dependent angiogenesis pathway. The gene discussed is SFT2D1; the disease is cervical carcinoma.